CA2218714A1 - Dosage form comprising oxybutynin - Google Patents

Dosage form comprising oxybutynin

Info

Publication number
CA2218714A1
CA2218714A1 CA002218714A CA2218714A CA2218714A1 CA 2218714 A1 CA2218714 A1 CA 2218714A1 CA 002218714 A CA002218714 A CA 002218714A CA 2218714 A CA2218714 A CA 2218714A CA 2218714 A1 CA2218714 A1 CA 2218714A1
Authority
CA
Canada
Prior art keywords
oxybutynin
dosage form
composition
disclosed
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002218714A
Other languages
French (fr)
Other versions
CA2218714C (en
Inventor
George V. Guittard
Francisco Jao
Susan M. Marks
David J. Kidney
Fernando Gumucio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corporation
George V. Guittard
Francisco Jao
Susan M. Marks
David J. Kidney
Fernando Gumucio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23770440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2218714(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corporation, George V. Guittard, Francisco Jao, Susan M. Marks, David J. Kidney, Fernando Gumucio filed Critical Alza Corporation
Priority to CA002510391A priority Critical patent/CA2510391A1/en
Publication of CA2218714A1 publication Critical patent/CA2218714A1/en
Application granted granted Critical
Publication of CA2218714C publication Critical patent/CA2218714C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition comprising oxybutynin and a device comprising oxybutynin are disclosed for oxybutynin therapy.
CA002218714A 1995-05-22 1996-05-08 Dosage form comprising oxybutynin Expired - Lifetime CA2218714C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002510391A CA2510391A1 (en) 1995-05-22 1996-05-08 Dosage form comprising oxybutynin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/445,849 1995-05-22
US08/445,849 US5674895A (en) 1995-05-22 1995-05-22 Dosage form comprising oxybutynin
PCT/US1996/006639 WO1996037202A1 (en) 1995-05-22 1996-05-08 Dosage form comprising oxybutynin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002510391A Division CA2510391A1 (en) 1995-05-22 1996-05-08 Dosage form comprising oxybutynin

Publications (2)

Publication Number Publication Date
CA2218714A1 true CA2218714A1 (en) 1996-11-28
CA2218714C CA2218714C (en) 2005-08-23

Family

ID=23770440

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002218714A Expired - Lifetime CA2218714C (en) 1995-05-22 1996-05-08 Dosage form comprising oxybutynin
CA002510391A Abandoned CA2510391A1 (en) 1995-05-22 1996-05-08 Dosage form comprising oxybutynin

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002510391A Abandoned CA2510391A1 (en) 1995-05-22 1996-05-08 Dosage form comprising oxybutynin

Country Status (14)

Country Link
US (2) US5674895A (en)
JP (2) JPH11505264A (en)
KR (1) KR100404954B1 (en)
AU (2) AU695194B2 (en)
BE (1) BE1009462A3 (en)
CA (2) CA2218714C (en)
CH (1) CH690955A5 (en)
DE (1) DE19681389B3 (en)
FR (1) FR2734483B1 (en)
GB (1) GB2318055B (en)
IT (1) IT1285345B1 (en)
NL (1) NL1003185C2 (en)
NZ (1) NZ307116A (en)
WO (1) WO1996037202A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
ES2141044B1 (en) * 1997-02-26 2001-02-01 Alza Corp OXIBUTININE THERAPY.
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
AU1534699A (en) * 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
AR018321A1 (en) * 1998-03-26 2001-11-14 Alza Corp A DOSAGE FORM OF PROLONGED LIBERATION THAT INCLUDES OXIBUTININE AND THE USES OF OXIBUTININE AND THE DOSAGE FORM OF PROLONGED LIBERATION.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
AU1256399A (en) * 1998-10-07 2000-04-26 Alza Corporation Controlled release dosage from comprising oxybutynin
WO2000064528A1 (en) * 1999-04-28 2000-11-02 Situs Corporation Drug delivery system
WO2000076490A2 (en) * 1999-06-10 2000-12-21 Sepracor Inc. Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
CN101305994A (en) * 2000-04-26 2008-11-19 沃特森药物公司 Minimizing adverse experience associated with oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
IT1318674B1 (en) * 2000-08-08 2003-08-27 Nicox Sa DO IT FOR INCONTINENCE.
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
KR101045144B1 (en) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
WO2002074285A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
HUP0402611A2 (en) * 2001-10-08 2005-07-28 Sun Pharmaceutical Industries Limited An antispasmodic agent spaced drug delivery system
DE10149674A1 (en) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
EP1558563A1 (en) * 2002-10-29 2005-08-03 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
AR053986A1 (en) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent OSMOTIC DEVICE CONTAINING AMANTADINE AND AN OSMOTIC SALT
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) * 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) * 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
KR20110071064A (en) 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 Compositions and methods of using (r)-pramipexole
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
CA2765876A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS61539B1 (en) 2013-07-12 2021-04-29 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
JP6841834B2 (en) 2016-01-20 2021-03-10 テラヴィダ, インコーポレイテッドTheraVida, Inc. Methods and compositions for the treatment of hyperhidrosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4800098A (en) * 1984-09-19 1989-01-24 J. R. Simplot Method of preserving potatoes
BE902605A (en) * 1985-06-06 1985-09-30 Therabel Res S A N V Medicaments for treating urinary tract disorders - contg. oxybutynin chloride
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2665858B2 (en) * 1992-05-30 1997-10-22 日本ヘキスト・マリオン・ルセル株式会社 Long-acting oxybutynin hydrochloride preparation
JP2646170B2 (en) * 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 Sustained-release oxybutynin hydrochloride preparation
JP3066515B2 (en) * 1992-11-11 2000-07-17 久光製薬株式会社 Transdermal formulation for treatment of urinary incontinence
CA2165802A1 (en) * 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin

Also Published As

Publication number Publication date
GB2318055B (en) 1999-07-21
AU695194B2 (en) 1998-08-06
GB2318055A (en) 1998-04-15
NZ307116A (en) 1999-03-29
CA2510391A1 (en) 1996-11-28
CH690955A5 (en) 2001-03-15
ITTO960427A0 (en) 1996-05-21
KR100404954B1 (en) 2004-04-28
US5674895A (en) 1997-10-07
NL1003185C2 (en) 1996-12-03
AU718849B2 (en) 2000-04-20
AU5639296A (en) 1996-12-11
GB9723081D0 (en) 1998-01-07
IT1285345B1 (en) 1998-06-03
US5840754A (en) 1998-11-24
FR2734483B1 (en) 1997-07-11
JPH11505264A (en) 1999-05-18
FR2734483A1 (en) 1996-11-29
KR19990021879A (en) 1999-03-25
DE19681389T1 (en) 1998-04-23
ITTO960427A1 (en) 1997-11-21
DE19681389B3 (en) 2015-12-10
MX9709013A (en) 1998-03-31
WO1996037202A1 (en) 1996-11-28
BE1009462A3 (en) 1997-04-01
AU9052298A (en) 1999-01-14
CA2218714C (en) 2005-08-23
NL1003185A1 (en) 1996-11-25
JP2007197462A (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CA2218714A1 (en) Dosage form comprising oxybutynin
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
CA2186260A1 (en) Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide
AUPN605795A0 (en) Analgesic pharmaceutical composition
AUPN411195A0 (en) Medicinal composition
GB9519363D0 (en) Pharmaceutical formulation
HUP9802913A3 (en) Bioadhesive solid dosage form
AU4050195A (en) Soft gelatin pharmaceutical dosage form
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP0862431A4 (en) Pharmaceutical formulation
AU7002296A (en) Analgesic composition
AU7923294A (en) Senna dosage form
AU2148095A (en) Fuel treatment device
GB9523566D0 (en) Pharmaceutical formulation
ZA96796B (en) Transdermal formulation.
ZA96526B (en) Novel pharmaceutical formulation
AUPN727595A0 (en) Therapeutic compositions
AU6230296A (en) Fuel treatment device
AU7190496A (en) Therapeutic compositions
AU679162B3 (en) Therapeutic compositions
AU6470996A (en) 4a-aryldecahydroisoquinoline compounds and medicinal uses thereof
AU6839796A (en) "tel" series complex distribution mechanism
AU2952289A (en) Tetracycline dosage form
AUPN180895A0 (en) Medicinal composition

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160509